NCT03501979
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: Leptomeningeal Disease
Additional Notes: Patients must have evidence of leptomeningeal disease (LMD) 
Exclusions: 
https://ClinicalTrials.gov/show/NCT03501979